TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer

International Journal of Oncology

Volumn 47, Issue 3, 2015, Pages 857-866

  Grimmig, Tanja ^a   Matthes, Niels ^a   Hoeland, Katharina ^a   Tripathi, Sudipta ^b   Chandraker, Anil ^b   Grimm, Martin ^c   Moench, Romana ^a   Moll, Eva Maria ^a   Friess, Helmut ^d   Tsaur, Igor ^e   Blaheta, Roman A ^e   Germer, Cristoph T ^a   Waaga Gasser, Ana Maria ^a,b   Gasser, Martin ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e GOETHE UNIVERSITY   (Germany)

Author keywords

Agonists; Inflammation; Pancreatic cancer; TLR7; TLR8

Indexed keywords

CYCLOOXYGENASE 2; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RESIQUIMOD; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; IMIDAZOLE DERIVATIVE; TLR7 PROTEIN, HUMAN; TLR8 PROTEIN, HUMAN;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CHEMOSENSITIVITY; CHRONIC PANCREATITIS; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING; ANIMAL; CANCER TRANSPLANTATION; DRUG EFFECTS; GENETICS; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; RETROSPECTIVE STUDY; TUMOR CELL LINE;

AGED; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMIDAZOLES; MICE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 84938054082     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3069     Document Type: Article

References (35)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Saif MW: Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP 8: 545-552, 2007.
3. Saif MW: Pancreatic neoplasm in 2011: An update. JOP 12: 316-321, 2011.
4. Balkwill F and Coussens LM: Cancer: An inflammatory link. Nature 431: 405-406, 2004.
5. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
6. Greten FR and Karin M: The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett 206: 193-199, 2004.
7. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammationassociated cancer. Nature 431: 461-466, 2004.
8. Ketloy C, Engering A, Srichairatanakul U, Limsalakpetch A, Yongvanitchit K, Pichyangkul S and Ruxrungtham K: Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates. Vet Immunol Immunopathol 125: 18-30, 2008.
9. Ochi A, Graffeo CS, Zambirinis CP, Rehman A, Hackman M, Fallon N, Barilla RM, Henning JR, Jamal M, Rao R, et al: Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest 122: 4118-4129, 2012.
10. Cherfils-Vicini J, Platonova S, Gillard M, Laurans L, Validire P, Caliandro R, Magdeleinat P, Mami-Chouaib F, Dieu-Nosjean MC, Fridman WH, et al: Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 120: 1285-1297, 2010.
11. Janeway CA Jr: Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54: 1-13, 1989.
12. Rubartelli A and Lotze MT: Inside, outside, upside down: Damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol 28: 429-436, 2007.
13. Grimm M, Kim M, Rosenwald A, Heemann U, Germer CT, Waaga-Gasser AM and Gasser M: Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression. Eur J Cancer 46: 2849-2857, 2010.
14. Bowie A and O'Neill LA: The interleukin-1 receptor/Toll-like receptor superfamily: Signal generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol 67: 508-514, 2000.
15. Harris RE: Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem 42: 93-126, 2007.
16. Bong AB, Bonnekoh B, Franke I, Schön M, Ulrich J and Gollnick H: Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 205: 135-138, 2002.
17. Dunne A, Marshall NA and Mills KH: TLR based therapeutics. Curr Opin Pharmacol 11: 404-411, 2011.
18. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825, 2011.
19. Chang YJ, Wu MS, Lin JT and Chen CC: Helicobacter pyloriinduced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. J Immunol 175: 8242-8252, 2005.
20. de Moraes E, Dar NA, de Moura Gallo CV and Hainaut P: Crosstalks between cyclooxygenase-2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis. Int J Cancer 121: 929-937, 2007.
21. Dvorak HF: Angiogenesis: Update 2005. J Thromb Haemost 3: 1835-1842, 2005.
22. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS and Sweeney CJ: Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 21: 139-146, 2000.
23. Hattermann K, Picard S, Borgeat M, Leclerc P, Pouliot M and Borgeat P: The Toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis. FASEB J 21: 1575-1585, 2007.
24. Meteoglu I, Erdogdu IH, Meydan N, Erkus M and Barutca S: NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues. J Exp Clin Cancer Res 27: 53, 2008.
25. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15: 2403-2413, 1997.
26. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D and Sarkar FH: Pancreatic cancer: Understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 8: 27-33, 2011.
27. Güngör C, Zander H, Effenberger KE, Vashist YK, Kalinina T, Izbicki JR, Yekebas E and Bockhorn M: Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Cancer Res 71: 5009-5019, 2011.
28. Hu X, Chung AY, Wu I, Foldi J, Chen J, Ji JD, Tateya T, Kang YJ, Han J, Gessler M, et al: Integrated regulation of Toll-like receptor responses by Notch and interferon-gamma pathways. Immunity 29: 691-703, 2008.
29. Hemmi H, Noike M, Nakayama T and Nishino T: Change of product specificity of hexaprenyl diphosphate synthase from Sulfolobus solfataricus by introducing mimetic mutations. Biochem Biophys Res Commun 297: 1096-1101, 2002.
30. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, Lipford G and Bauer S: Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 3: 499, 2002.
31. Scheel B, Aulwurm S, Probst J, Stitz L, Hoerr I, Rammensee HG, Weller M and Pascolo S: Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur J Immunol 36: 2807-2816, 2006.
32. Sauder DN, Smith MH, Senta-McMillian T, Soria I and Meng TC: Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob Agents Chemother 47: 3846-3852, 2003.
33. Chiron D, Pellat-Deceunynck C, Amiot M, Bataille R and Jego G: TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production. J Immunol 182: 4471-4478, 2009.
34. Hsu RY, Chan CH, Spicer JD, Rousseau MC, Giannias B, Rousseau S and Ferri LE: LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis. Cancer Res 71: 1989-1998, 2011.
35. Thuringer D, Hammann A, Benikhlef N, Fourmaux E, Bouchot A, Wettstein G, Solary E and Garrido C: Transactivation of the epidermal growth factor receptor by heat shock protein 90 via Toll-like receptor 4 contributes to the migration of glioblastoma cells. J Biol Chem 286: 3418-3428, 2011.